Amalgamated Financial’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Amalgamated Financial’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$7K	Buy	+266	New	+$9.68K	﹤0.01%	2943

Other funds holding ONCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's ONCT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2022: 266 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #2943 among its holdings.

78 funds tracked by Wall St. Rank hold ONCT as of Q1 2022.

Amalgamated Financial held 266 shares of Oncternal Therapeutics, Inc. Common Stock worth $7K as of Q1 2022.
Oncternal Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2943 holding.
78 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.